GTN Ltd is building the world’s most efficient technology for drug discovery: Generative Tensorial Networks. Our technology addresses the main challenges in the search for new drugs with novel technology built on recent interdisciplinary developments in the fields of machine learning and quantum physics, in order to simulate, analyse and search for new chemical compounds. The company is based in central London and run by a passionate and highly skilled team of quantum physicists, machine learning experts, and chemists.
GTN has some of the world’s brightest minds on its advisory board. Their other roles include directing the Max Planck Institute, Professors at Cambridge university, UCL and Ghent university, and Fellow of the Royal Society of Chemistry.
GTN is backed by Tier 1 investors from Europe and US (their other investments include Rigetti Computing and Magic Pony).